Browsing Category
Pharma Industry News
4724 posts
Business-News-Today.com section for global pharma industry news, Indian pharma sector latest news, pharma sector news today, pharmaceuticals industry news.
How EMA’s support for EURneffy 1 mg could disrupt Europe’s pediatric epinephrine market
EMA backs EURneffy 1 mg for pediatric anaphylaxis. Find out how ARS Pharmaceuticals and ALK-Abelló could reshape Europe’s allergy care landscape.
How FDA scrutiny of packaging and administration stalled Anaphylm despite clinical comparability to auto-injectable epinephrine
FDA scrutiny stalled Anaphylm despite strong clinical data. Find out what this means for epinephrine innovation, regulatory risk, and investor expectations.
Can prescription discounts improve uptake of FDA-approved malaria prevention drugs in 2026?
Can tafenoquine’s GoodRx discount model reset malaria drug access strategy? Read how retail-driven pricing may reshape travel health in 2026.
GSK FY2025 results show momentum in HIV and oncology while vaccines and general medicines face pressure
GSK’s FY2025 core EPS grew 12 percent with strong Specialty Medicines performance. Find out how the company is planning to sustain momentum in 2026.
Why predictive biomarkers may determine ALX Oncology’s competitive viability in HER2-positive breast cancer
Find out why CD47 biomarkers could determine ALX Oncology’s ability to compete in HER2-positive breast cancer and what risks remain for evorpacept.
How Quantum Scan’s platform ambition tests the economics of early disease detection at scale
How Quantum Scan’s platform ambition exposes the economic, regulatory, and reimbursement realities shaping early disease detection at scale.
Lilly selects Lehigh Valley, Pennsylvania for obesity drug manufacturing plant
Lilly is building a $3.5B injectable medicine facility in Pennsylvania to scale retatrutide. Find out how this reshapes the obesity drug market and U.S. supply.
Ipsen secures global licensing option for Origami’s selective protein degrader platform
Ipsen has signed a global option deal with Origami Therapeutics for a rare CNS protein degrader. Find out what this signals for neuro drug strategy.
Why did the FDA double down on rejecting Corcept’s flagship drug? Investors rattled
Corcept Therapeutics faces fresh regulatory headwinds as the FDA revises its relacorilant rejection letter, highlighting safety concerns and strategic missteps. Read more.
Sanofi’s second chance: Why Europe is warming up to Rezurock after initial CHMP rejection
Sanofi’s Rezurock secures EU conditional approval recommendation for chronic GVHD. Find out what changed and how this could reshape rare disease care.